Technologies

This innovative technology involves the use of a high-affinity, highly specific antibody that targets extracellular domains of connexin hemichannels (Cx26, Cx30, and Cx32). The antibody has been designed to reduce or inhibit the growth of brain tumors, particularly glioblastoma (GBM), and to alleviate the associated epilepsy. By blocking connexin hemichannels, the antibody interferes with pathological ATP release and other signaling mechanisms that contribute to tumor progression and neural hyperexcitability.

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

Silicon nanowires (SiNWs) are 1D structures with diameter ranging from few tens to hundreds of nanometers and length varying from few tens of nanometers to millimiters. SiNWs are fabricated in the labs of the IMM-CNR, Rome Unit,  by using bottom-up technologies such as plasma enhanced chemical vapor deposition (PECVD) at low growth temperature ((≤350°C), allowing the use of plastic and glassy substrates. Their electrical properties can be tuned by controlling the p/n doping during the growth.

The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.

Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

Severe asthma or chronic obstructive pulmonary disease (COPD) are nowadays associated with a poor response to corticosteroids which led to the use of high-dose with consequent improved onset of side effects. The use of nanotechnologies can represent an innovative approach for the effective treatment of both asthma and COPD. The development of new nano-formulations involving the use of nanomaterials and specifically tailored to be inhaled offers numerous advantages over conventional inhaled dosage forms.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

Combinations of several enzymes in a production chain are preferred to “first generation” enzymatic processes (where the "single reaction - single enzyme" principle was followed), for the synthesis of compounds with high added value starting from simple and cheap substrates. An important requirement for obtaining control in "cascade enzymatic reactions" is the ability to deliver from one biocatalyst to the next one the various intermediates, limiting as much as possible the diffusion of the latter in the solvent.

Our proposal focuses on innovative formulations containing metallic complexes and plant extracts for diabetes treatment. The formulations were tested in vitro on human adipocyte cell models, showing a strong hypoglycemic effect due to the synergistic action of the two components. The plant extracts, derived from waste biomass of the agri-food industry, possess high antioxidant activity and interesting nutraceutical properties, due to their composition rich in polyphenols.

The technology concerns planar optical antennas composed of thin metal films and dielectric materials for the efficient direction of the light emitted by light sources, such as fluorescent molecules and bio-markers. They consist of a reflector layer, adjacent to the substrate, and a director, semi-reflective, between which the emitter is positioned, integrated into a homogeneous dielectric layer.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

Currently, liposomes (artificially synthesised vesicles) are widely used as carriers for a variety of molecules in the cosmetic and pharmaceutical industries. In the clinical applications, for instance, they are employed to encapsulate a range of substances, such as antibiotics, proteins, genetic material, vitamins and anti-cancer drugs.

The development of an innovative screening platform of natural marine extracts guided by biological assays represents one of the main products developed within the Antitumor Drugs and Vaccines from the SEA (ADViSE) project which aims to provide a new vision in Drug Discovery processes.